For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.
Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This educational activity is supported by an independent medical education grant from GSK.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.5
22 ratings
For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.
Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This educational activity is supported by an independent medical education grant from GSK.
Disclosure information is available at the beginning of the video presentation.
28 Listeners
10 Listeners
5 Listeners
10 Listeners
4 Listeners
2 Listeners
4 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
12 Listeners
4 Listeners
3 Listeners
5 Listeners